Abstract
In cancer, neovascularization seems necessary for tumor progression and metastasis. The hypothesis that cancer progression is angiogenesis-dependent has repeatedly been confirmed by experimental inhibition of tumor growth with angiogenesis inhibitors. Receptors for VEGF (VEGFRs) are expressed on tumor endothelium and tumor cells and, as expected, VEGF-A overexpression is associated with poor prognosis (reduced survival). There are both positive and negative angiogenesis regulators and, as such, two strategies for inhibiting pathologic angiogenesis can be adopted: the inhibition of positively-acting agents (e.g., VEGFR inhibitors) and the administration of negatively-acting agents (e.g., angiostatin (from the Greek words "angio" and "stasis" meaning stopping)).
Keywords: Angiogenesis, Anti-angiogenesis drugs, Cancer, Growth factors, Negative angiogenesis regulators, Positive angiogenesis regulators.
Related Journals
Drug Delivery Letters
Recent Advances in Anti-Infective Drug Discovery
Applied Drug Research, Clinical Trials and Regulatory Affairs
Current Bioactive Compounds
Current Drug Delivery
Current Drug Safety
Drug Metabolism and Bioanalysis Letters
Recent Advances in Drug Delivery and Formulation
Reviews on Recent Clinical Trials
Current Drug Targets - Inflammation & Allergy
Related Books
A Comprehensive Text Book on Self-emulsifying Drug Delivery Systems
Angiogenesis & Therapeutic Targets In Cancer
Biopolymers In Drug Delivery: Recent Advances and Challenges
Chemoinformatics: Directions Toward Combating Neglected Diseases
Current Advances in Drug Delivery Through Fast Dissolving/Disintegrating Dosage Forms
Current Technologies To Increase The Transdermal Delivery Of Drugs
Current Technologies To Increase The Transdermal Delivery Of Drugs
Drug Design and Discovery in Alzheimer's Disease
Frontiers in Anti-Cancer Drug Discovery
Frontiers in Anti-Cancer Drug Discovery